Wells Fargo & Company Tricida, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$8.51 - $13.6 $3,199 - $5,113	-376 Reduced 14.33%	2,248 $24,000
Q2 2022 Aug 12, 2022	BUY	$7.31 - $11.85 $3,830 - $6,209	524 Added 24.95%	2,624 $25,000
Q1 2022 May 16, 2022	SELL	$7.35 - $10.63 $316 - $457	-43 Reduced 2.01%	2,100 $17,000
Q4 2021 Feb 14, 2022	BUY	$4.19 - $9.56 $419 - $956	100 Added 4.89%	2,143 $20,000
Q3 2021 Nov 15, 2021	SELL	$3.56 - $4.64 $3,382 - $4,408	-950 Reduced 31.74%	2,043 $9,000
Q2 2021 Aug 16, 2021	SELL	$3.95 - $5.41 $16,005 - $21,921	-4,052 Reduced 57.52%	2,993 $13,000
Q1 2021 May 13, 2021	SELL	$4.52 - $7.8 $73,838 - $127,420	-16,336 Reduced 69.87%	7,045 $37,000
Q4 2020 Feb 09, 2021	BUY	$4.37 - $9.46 $46,706 - $101,108	10,688 Added 84.2%	23,381 $164,000
Q3 2020 Nov 05, 2020	SELL	$8.56 - $26.93 $18,275 - $57,495	-2,135 Reduced 14.4%	12,693 $115,000
Q2 2020 Aug 13, 2020	BUY	$21.21 - $31.55 $65,941 - $98,088	3,109 Added 26.53%	14,828 $408,000
Q1 2020 May 14, 2020	BUY	$18.43 - $38.04 $215,981 - $445,790	11,719 New	11,719 $258,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.